Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes. The efficacy and safety of once-weekly tirzepatide as compared with semaglutide, a selective GLP-1 receptor agonist, are unknown. METHODS: In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg. At baseline, the mean glycated hemoglobin level was 8.28%, the mean age 56.6 years, and the mean weight 93.7 kg. The primary end point was the change in the glycated hemoglobin level from baseline to 40 weeks. RESULTS: The estimated mean change from baseline in the glycated hemoglobin level was -2.01 percentage points, -2.24 percentage points, and -2.30 percentage points with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and -1.86 percentage points with semaglutide; the estimated differences between the 5-mg, 10-mg, and 15-mg tirzepatide groups and the semaglutide group were -0.15 percentage points (95% confidence interval [CI], -0.28 to -0.03; P = 0.02), -0.39 percentage points (95% CI, -0.51 to -0.26; P<0.001), and -0.45 percentage points (95% CI, -0.57 to -0.32; P<0.001), respectively. Tirzepatide at all doses was noninferior and superior to semaglutide. Reductions in body weight were greater with tirzepatide than with semaglutide (least-squares mean estimated treatment difference, -1.9 kg, -3.6 kg, and -5.5 kg, respectively; P<0.001 for all comparisons). The most common adverse events were gastrointestinal and were primarily mild to moderate in severity in the tirzepatide and semaglutide groups (nausea, 17 to 22% and 18%; diarrhea, 13 to 16% and 12%; and vomiting, 6 to 10% and 8%, respectively). Of the patients who received tirzepatide, hypoglycemia (blood glucose level, <54 mg per deciliter) was reported in 0.6% (5-mg group), 0.2% (10-mg group), and 1.7% (15-mg group); hypoglycemia was reported in 0.4% of those who received semaglutide. Serious adverse events were reported in 5 to 7% of the patients who received tirzepatide and in 3% of those who received semaglutide. CONCLUSIONS: In patients with type 2 diabetes, tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks. (Funded by Eli Lilly; SURPASS-2 ClinicalTrials.gov number, NCT03987919.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationDavies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Self-citationGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Self-citationCoskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882
Self-citationFrias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815
Self-citationPratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30024-x · Cited by 790
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745
Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596
Cited by
Items 1,501–1,600 of 2,039
Next Step in Incretin-Based Therapy: From Single to Dual Agonism
Pramanik, S., & Ray, S. (2022) · EMJ Diabetes · doi:10.33590/emjdiabet/22-00140 · Cited by 2
Kettős inkretinterápia – új lehetőség a 2-es típusú diabetes vércukorcsökkentő kezelésében
Winkler, G., Kis, J. T., & Schandl, L. (2022) · Lege Artis Medicinae · doi:10.33616/lam.32.019 · Cited by 4
Les approches thérapeutiques non invasives de l’obésité : hier, aujourd’hui et demain
Galmiche, M. C., & Déchelotte, P. (2022) · Nutrition Clinique et Métabolisme · doi:10.1016/j.nupar.2022.09.001 · Cited by 2
Therapieoptionen bei Weight-Regain nach Bariatrischer Operation
Finze, A., Otto, M., Reißfelder, C., & Blank, S. (2022) · Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie · doi:10.1055/a-1957-5570 · Cited by 1
“[40] Frias JP, Davies MJ, Rosenstock J et al.”
BackgroundTirzepatide, una nuova frontiera nel trattamento dell’obesità
Guarini, F., & Laviola, L. (2023) · L Endocrinologo · doi:10.1007/s40619-023-01219-4 · Cited by 1
“Nel SURPASS-2, invece, è stata dimostrata la superiorità di Tirzepatide rispetto alla Semaglutide al dosaggio di 1 mg, sia in termini di calo ponderale, sia di controllo glicemico in pazienti affetti da diabete mellito tipo 2 [3].”
BackgroundТкач, С. М., Pankiv, V. І., & Yuzvenko, Т. Y. (2023) · Clinical endocrinology and endocrine surgery · doi:10.30978/cees-2023-1-47 · Cited by 2
Diabetes Management in the United States
Shah, M. K., Khan, F. N., & Ali, M. K. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_19 · Cited by 1
Patient-reported outcome measures after metabolic surgery
Mingrone, G., Castagneto‐Gissey, L., & Bornstein, S. R. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00173-0 · Cited by 2
A duális antidiabetikus hatású kombináció, a tirzepatid
Gerő, L. (2023) · Diabetologia Hungarica · doi:10.24121/dh.2023.4
Pharmacotherapy of Obesity and Metabolic Syndrome
Duan, D., & Ahima, R. S. (2023) · Springer eBooks · doi:10.1007/978-3-031-40116-9_44 · Cited by 4
Obesity and Metabolic Syndrome in the United States
Osei, A. D., Ohene-Kyei, E. T., & Echouffo-Tcheugui, J. B. (2023) · Springer eBooks · doi:10.1007/978-3-031-40116-9_55 · Cited by 1
Is clinical trial data showing positive progress for the treatment of diabetic kidney disease?
Tan, S. K., & Cooper, M. E. (2023) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2023.2277762 · Cited by 1
Bradley, C. L., McMillin, S. M., Hwang, A. Y., & Sherrill, C. H. (2024) · Annals of Pharmacotherapy · doi:10.1177/10600280231224021 · Cited by 1
Enzan, N., Miyazawa, K., Koyama, S., Kurosawa, R., Ieki, H., Yoshida, H., Takechi, F., Fukuyama, M., Osako, R., Tomizuka, K., et al. (2024) · medRxiv · doi:10.1101/2024.11.14.24317249 · Cited by 1
Treatment of obesity-related HFpEF: a STEP closer to the SUMMIT
Karakasis, P., Fragakis, N., Ruža, I., Stachteas, P., & Patoulias, D. (2025) · Future Cardiology · doi:10.1080/14796678.2025.2477429 · Cited by 2
Individual Variability in the Cardiometabolic Response to Tirzepatide
Khan, S. U., Pandey, A., & Nasir, K. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.04.004 · Cited by 1
Edvardsson, C. E., Adermark, L., Gottlieb, S., Alfreji, S., Emous, T. A., Gouda, Y., Thorsell, A., Vujičić, M., Aranäs, C., Benrick, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.26.672374 · Cited by 1
Incretin-based therapies for obesity and disordered eating: optimising care in general practice
Atlantis, E. E., Wu, R., & Dixon, J. (2026) · Family Medicine and Community Health · doi:10.1136/fmch-2025-003622 · Cited by 2
Governor, S., Essien, E., Agyekum, A. K., Ahsan, A., Wiesel, S., Khurana, D., El‐Kersh, K., Altaee, O., Otchere, P., & Dávila‐Román, V. G. (2026) · medRxiv · doi:10.64898/2026.01.20.26344489 · Cited by 1
Therapie der Adipositas mit Semaglutid
Blüher, M., & Nitschmann, S. (2021) · Der Internist · doi:10.1007/s00108-021-01119-5 · Cited by 1
Tirzepatide: A Useful Addition for Treatment of Type 2 Diabetes and Obesity
Mikhail, N. (2021) · Gastroenterology Pancreatology and Hepatobilary Disorders · doi:10.31579/2641-5194/044
Halimi, S. (2021) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2021.10.019
Ritzel, R. A. (2021) · Diabetologie und Stoffwechsel · doi:10.1055/a-1687-3008
Kongress der American Diabetes Association: Individualisierung auf allen Ebenen der Therapie
Arand, M. (2021) · Deutsches Ärzteblatt · doi:10.3238/persdia.2021.11.05.01
Overview of the 81st Scientific Sessions of the American Diabetes Association
Day, C. (2021) · British Journal of Diabetes · doi:10.15277/bjd.2021.331
Vergleich der blutglukosesenkenden Effekte von Tirzepatid und Semaglutid
Heinitz, S. (2022) · Der Diabetologe · doi:10.1007/s11428-022-00861-0
“Zudem vermutet man, dass die zentrale GLP1-abhängige Inhibition der Nahrungsaufnahme durch den GIP-Agonismus verstärkt wird [4, 5].”
BackgroundIm Vergleich: Tirzepatid versus Semaglutid einmal wöchentlich
Andres, U. (2022) · Diabetologie und Stoffwechsel · doi:10.1055/a-1701-1268
Management of Type 2 Diabetes in Stage C Heart Failure with Reduced Ejection Fraction
Agarwalla, A., Gruen, J., Peters, C. J., Sinnenberg, L. E., OWENS, A. T., & Reza, N. (2022) · Cardiac failure review · doi:10.15420/cfr.2021.31
Sachs, S., Götz, A., Finan, B., DiMarchi, R. D., Döring, Y., Weber, C., Tschöp, M. H., Müller, T. D., & Hofmann, S. M. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.15.484530
Neue Entwicklungen in der Therapie des Diabetes mellitus Typ 2
Hintze, S. C., & Terkamp, C. (2022) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1496-5414 · Cited by 1
Mannucci, E. (2022) · L Endocrinologo · doi:10.1007/s40619-022-01074-9
“La prima molecola di questa classe, la tirzepatide (a dosi di 5–15 mg alla settimana), si è mostrata ancora più efficace nella riduzione dell’emoglobina glicata rispetto all’agonista GLP-1 semaglutide 1 mg, con una simile tollerabilità [4].”
BackgroundInfluentialTirzepatid als Add-on bei Typ-2-Diabetes
(2022) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1779-5740
and, E. J., & Fisher, M. (2022) · Wiley eBooks · doi:10.1002/9781119785033.ch14
Appetite Control Mechanisms and Obesity
Roh, E. (2022) · Journal of Korean Diabetes · doi:10.4093/jkd.2022.23.2.89
“과체중의 2형당뇨병 환자를 대상으 로 한 SURPASS-2 (A study of tirzepatide [LY3298176] versus semaglutide once weekly as add-on therapy to metformin in participants with type 2 diabetes) 연구 에서 40주간의 매주 티르제파타이드 치료는 테스트한 모든 용량에서 세마글루타이드 1 mg에 비해 당화혈색소 강하 효 과와 체중감소 모두에서 매우 우수한 결과를 보였다[39].”
Druzhilov, M., Kuznetsova, T. Y., & Chumakova, G. (2021) · Russian Journal of Cardiology · doi:10.15829/29/1560-4071-2022-4755 · Cited by 3
Vergleich verschiedener Dosierungen von Tirzepatid und Semaglutid bei Typ-2-Diabetes
KAHL, S. (2022) · Die Diabetologie · doi:10.1007/s11428-022-00938-w
“Inder SURPASS-2-Studie [1] waren alle getesteten Tirzepatiddosierungen (5, 10 und 15mg/wöchentlich subkutan [s.c.]) Semaglutid in der Dosierung 1mg/Woche s.c. überlegen, sowohl im Hinblick auf die Senkung des glykierten Hämoglobins A1 (HbA1c) als auch die Reduktion des Körpergewichts bei Personen mit unzureichend eing…”
BackgroundInfluentialSecretion and Impact of Gut Hormones in Obesity and Diabetes
Holst, J. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821618-7.00264-9
En quoi la prise en charge de l’hypertendu diabétique est-elle différente?
Teso, A. D., Lamine, F., Zanchi, A., & Wuerzner, G. (2022) · JMIG · doi:10.53738/revmed.2022.18.795.1710
Adipositas: Neue Hoffnung durch Medikamente oder Ernährungsstrategien?
von Sengbusch, A. (2022) · Ernährung & Medizin · doi:10.1055/a-1908-5021
“Dieser GLP-1/GIP (glucose dependent insulinotropic polypeptide) -Co-Ago - nist führte, einmal wöchentlich angewendet, in der Sur-pass 2 Studie bei Menschen mit Typ-2-Diabetes und Adi-positas zu einer Gewichtsreduktion von bis zu 13 % und war damit im direkten Vergleich Semaglutid überlegen [8].”
BackgroundSuboptimal Weight Loss After Bariatric Surgery: Mechanisms and Treatment Algorithms
Mok, J., & Batterham, R. L. (2022) · Springer eBooks · doi:10.1007/978-3-030-54064-7_118-1
Reversion and remission are promising targets for patients with type 2 diabetes mellitus
Канорский, С. Г. (2022) · South Russian Journal of Therapeutic Practice · doi:10.21886/2712-8156-2022-3-3-7-16 · Cited by 1
Müller, T. D. (2022) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-1904-5552
“In Phase 3 des SURPASS-Programms wies Mounjaro dosisabhängig eine deutlich stärkere Senkung des HbA1c im Vergleich zu Semaglutide 1 mg [6], Insulin Glargine [5] und Insulin Degludec [7] Eine oft diskutierte Frage ist, warum sich die Wirksamkeit der GIPR/ GLP-1R-Ko-Agonisten so stark von bisherigen…”
Aberle, J., Lautenbach, A., Meyhöfer, S., Meyhöfer, S. M., Menzen, M., Selig, L., & Blüher, M. (2022) · Diabetologie und Stoffwechsel · doi:10.1055/a-1886-3659
Dualer Ansatz lässt die Pfunde schmelzen
Diener, H.-C. (2022) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-022-3022-9
Efficience et précision du contrôle glycémique dans le diabète : symphonie inachevée ?
Monnier, L., Halimi, S., & Colette, C. (2022) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2022.11.005
Schlienger, J.-L., & Monnier, L. (2022) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2022.12.006 · Cited by 4
Mechanisms of GLP‒1 Receptor Agonists on the Cardio-Renal Protective Effects
Kuriyama, S., & Matsumoto, K. (2022) · Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics · doi:10.3999/jscpt.53.6_249
Tirzepatide, A New Antidiabetic Drug with Change in the Treatment of Patients with Type 2 Diabetes
Kim, S. K. (2022) · Journal of Korean Diabetes · doi:10.4093/jkd.2022.23.4.213
Gastrointestinale Hormone – zunehmende arzneitherapeutische Bedeutung bei Stoffwechselerkrankungen
Gallwitz, B. (2023) · Die Innere Medizin · doi:10.1007/s00108-022-01447-0
Effekte von Tirzepatid im Vergleich zu Insulin Glargin auf die Nierenfunktion bei Typ-2-Diabetes
Schürfeld, R. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01002-x
GLP -1 agonists for weight loss: What you need to know
Goldberg, J. F. (2023) · Current Psychiatry · doi:10.12788/cp.0318
Clinical Potential of Glucagon-like Peptide-1 Analogs in the Management of Diabesity
Sharma, N., & Singh, S. (2023) · Journal of Diabetology · doi:10.4103/jod.jod_102_22
Novel Anti-Obesity Pharmacotherapies
Ghomraoui, F., & Srivastava, G. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.110685
GLP-1-Mimetika — wegweisend zur Behandlung von Diabetes und Adipositas
Stemmer, K., & Müller, T. D. (2023) · BIOspektrum · doi:10.1007/s12268-023-1919-6
der Beek, A. B. V. D. A. (2023) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.637600695
Aberle, J., Lautenbach, A., Meyhöfer, S., Meyhöfer, S. M., Menzen, M., Selig, L., & Blüher, M. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01037-0
Hintze, S. C., & Terkamp, C. (2023) · Diabetes aktuell · doi:10.1055/a-2068-3412
“[24] Frias PJ, Davies MJ, Rosenstock J et al.”
BackgroundSachs, S., Götz, A., Finan, B., Feuchtinger, A., DiMarchi, R. D., Döring, Y., Weber, C., Tschöp, M. H., Müller, T. D., & Hofmann, S. M. (2023) · Research Square · doi:10.21203/rs.3.rs-2912233/v1
Will Tirzepatide Become a Game-Changer Anti-Obesity Drug?
Kumar, A. (2023) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2023.01.012
Incretin Therapies: Current Use and Emerging Possibilities
Schlögl, H., & Stümvoll, M. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_35
Lautenbach, A., Wiesch, C. S. Z., & Aberle, J. (2023) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2059-9064 · Cited by 1
Physiological Effects of Incretin and Its Regulation and Imitation by Functional Food Factors
Harada, N. (2023) · Nippon Eiyo Shokuryo Gakkaishi · doi:10.4327/jsnfs.76.141
Caerels, S., Mertens, A. C., Hulsmans, M., & Mathieu, C. (2023) · Tijdschrift voor Geneeskunde · doi:10.47671/tvg.78.22.181
Advances in GLP-1 receptor agonists for the treatment of type 2 diabetes
Hong, S. (2023) · BIO Web of Conferences · doi:10.1051/bioconf/20236101006
Die neuen Wunderdrogen - eine Einordnung aus kardiologischer Sicht
Schirmer, S. H. (2023) · Info Diabetologie · doi:10.1007/s15034-023-4512-7
Tirzépatide : les leçons du programme clinique SURPASS. Au-delà de l’équilibre glycémique
Guerci, B. (2023) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2023.06.003 · Cited by 2
Cutting Edge Developments in Diabetes
Clifton, P. M. (2023) · Diabetology · doi:10.3390/diabetology4030024
Tirzépatide : les leçons du programme clinique SURPASS
Bordier, L., Gourdy, P., & Guerci, B. (2023) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2023.07.001 · Cited by 2
Choice of Therapy in Obese Type 2 Diabetes
Jyotsna, V., & Deshmukh, S. (2022) · Chronicle of Diabetes Research and Practice · doi:10.4103/cdrp.cdrp_2_22
Reproduction and Anti-Obesity Medications: A Review of Current Evidence
Saldívar-Cerón, H. I. (2023) · The Journal of Reproduction · doi:10.58779/issn.2954-467x.tjor2023.v2.n2.27 · Cited by 2
Adipositastherapie – werden Pharmakotherapien die Alternative zur metabolischen Chirurgie sein?
Müller, T. D., & Blüher, M. (2023) · Gynäkologische Endokrinologie · doi:10.1007/s10304-023-00527-0
“In den SURPASS-Phase-III-Studien zeigte Tirzepatid eine deutlich stärkere Senkung von Hämoglobin A1c (HbA1c) als die Behandlung mit Semaglutid 1mg [3], Insulin glargin [2] oder Insulin degludec (.”
BackgroundAnti-obesity medications: Breakthroughs and limitations
Barbieri, R. L. (2023) · OBG Management · doi:10.12788/obgm.0295
“Tirzepatide causes substantial weight loss, similar to the effect of semaglutide.(14)”
BackgroundEl-Naas, R., Barenbaum, S. R., Shukla, A. P., & Aronne, L. J. (2023) · Contemporary Endocrinology · doi:10.1007/978-3-031-39721-9_10
Editorial: Brain dopaminergic mechanisms
Yang, B., Romanov, R. A., Xu, J., et al. (2023) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2023.1292511
“This is even more exciting given the recent FDA approval of dual receptor agonists tirzepatide that is superior to GLP-1 agonist semaglutide in treating diabetes at much higher doses but with similar mild to moderate side effects (Frías et al., 2021).”
BackgroundMüller, T. D. (2023) · Diabetologie und Stoffwechsel · doi:10.1055/a-2102-3927
Highlights from the Diabetes UK Professional Conference 2023
Bishop, K. (2023) · Prescriber · doi:10.1002/psb.2096
Inkretin-Agonisten: In 30 Jahren vom Geheimtipp zum Bestseller
Nauck, M. A. (2023) · Deutsches Ärzteblatt · doi:10.3238/persdia.2023.11.03.01
Tirzepatide: A promising treatment for obesity?
Niedbala, C. G., & Sprague, R. (2023) · JAAPA · doi:10.1097/01.jaa.0000979484.51712.33
Obesity and Metabolic Syndrome in the United States
Osei, A. D., Ohene-Kyei, E. T., & Echouffo-Tcheugui, J. B. (2023) · Springer eBooks · doi:10.1007/978-3-319-12125-3_55-1
Genetische Ursachen der Adipositas und ihre therapeutischen Implikationen
Rajcsanyi, L. S., Schmidt, J., Düerkop, S., Grote, L., Peters, T., Körner, A., Fischer‐Posovszky, P., & Hinney, A. (2023) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2185-6864
Alsaab, J. S. (2023) · Pharmacology Toxicology and Biomedical Reports · doi:10.5530/ptb.2023.9.3
Lautenbach, A., Wiesch, C. S. Z., & Aberle, J. (2023) · Aktuelle Ernährungsmedizin · doi:10.1055/a-2185-5427
“[12] Frías JP, Davies MJ, Rosenstock J et al.”
BackgroundSanyal, A. J., Muthiah, M. D., & Tan, E. X. X. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85732-1.00029-3
TINDAKAN PENGANIAYAAN ANAK ANAK DI BAWAH UMUR
Aisyah, I., & Panjaitan, J. D. (2023) · Blantika Multidisciplinary Journal · doi:10.57096/blantika.v2i2.97
Abdel-Malek, M., Thayabaran, D., & Miras, A. D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91707-0.00010-3
The cardiometabolic syndrome and vascular disease: pivotal role of insulin
Caldarera, T., Tannenbaum, J., & Shapiro, M. D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91707-0.00015-2
Veränderungen der Sekretion und biologischen Wirksamkeit von Inkretinhormonen bei Typ-2-Diabetes
Quast, D. R., & Nauck, M. A. (2024) · Die Diabetologie · doi:10.1007/s11428-023-01146-w
“In klinischen Studien stellte sich heraus, dass es deutlich stärker den HbA 1c - Wert senken (und oft normalisieren) kann als die wirksamsten selektiven GLP-1-Re-zeptor-Agonisten [11].”
Zhu, J., Huang, Y., Luo, Y., Wen, Y., Li, H., Li, W., Deng, Y., Shao, J., Huang, H., & Zhu, Z. (2024) · Research Square · doi:10.21203/rs.3.rs-3894429/v1
GLP-1 RECEPTORIŲ AGONISTŲ REIKŠMĖ 2 TIPO CUKRINIU DIABETU SERGANČIŲ PACIENČIŲ SVORIO MAŽINIMUI
Viliušytė, M., Maleckas, A., & Malinauskas, M. (2024) · Health Sciences · doi:10.35988/sm-hs.2024.021
“Septyniose publikacijose pacientai 2TCD koregavo tik metforminu kartu su tyrimo metu skiriamais GLP-1RA [25,31,32,36,37,40,41].”
BackgroundInfluentialObésité : entre pléthore thérapeutique et questionnements nécessaires
Halimi, S. (2024) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2024.01.013 · Cited by 1
Woch, B., Bereza, D., Sokołowska, K., Kulak, M., Moreau, I., Polańska, P., & Lang, M. (2024) · Journal of Education Health and Sport · doi:10.12775/jehs.2024.58.004 · Cited by 2
Diabetes and COVID-19 Outcomes: An Analysis of Freeman Health System Patients
Wiant, T., Schmidt, L., Srikakolapu, S., Beyersdorfer, N., Akhtar, M., Johnson, K., Stahl, G., Goade, D. S., & Arnce, R. D. (2024) · Cureus · doi:10.7759/cureus.54249
“The SURPASS-2 (A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes) trial showed that tirzepatide caused an absolute reduction in glycated hemoglobin (Hba1c) by an average of 2.3% in the 15 mg group [22].”
BackgroundInfluentialXia, X., Lin, Q., Zhou, Z. M., & Chen, Y. (2024) · iScience · doi:10.1016/j.isci.2024.109377 · Cited by 2
Aboshhran, A. M., Alqahtani, S. A., alqhtani, Y. M., Alharthi, A. S., Kahl, A. F., & Khormi, K. M. I. (2023) · Journal of Population Therapeutics and Clinical Pharmacology · doi:10.53555/jptcp.v30i2.4746
Age-related disease: Cardiovascular system
Nilsson, P. M., Fossel, M., Bean, J., & Khera, N. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15500-0.00010-4 · Cited by 2
c. Part III: Treatment with Antidiabetes Drugs—Effects on Blood Pressure and Central Hemodynamics
Nilsson, P. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15512-3.00011-8
Obesity and Current Treatment Approaches: A Comprehensive Review
Mathialagan, K., Madhumitha, R., Muralidharan, K., & Jang, S.-J. (2024) · Journal of Translational Gastroenterology · doi:10.14218/jtg.2023.00040 · Cited by 1
Review of Efficacy and Safety of Semaglutide in the Management of Obesity
Han, S., & Park, T. E. (2024) · Korean Journal of Clinical Pharmacy · doi:10.24304/kjcp.2024.34.1.1
Alarcón‐Romero, L. D. C., Zubillaga‐Guerrero, M. I., William, C. I. M., Illades‐Aguiar, B., García, A. M. E., Rivera, M. J. M., Barrera, J. A. P., Gómez‐Gómez, Y., & Hernández, M. V. (2024) · doi:10.22533/at.ed.8022401044
A CONEXÃO CURIOSA ENTRE DIABETES MELLITUS E A DOENÇA DE PARKINSON
Maciel, L. M., dos Santos, A. V. F., da Silva, C. V. B. G., dos Santos, G. L. G., Galdino, E. D. S., de Moraes, J. G. F., Miranda, M. A., Silva, M. A. P. D. C. C., Barbosa, J. O. L., & de Lira, A. C. L. (2024) · doi:10.22533/at.ed.8022401047
Metadata
- Authors
- Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K.
- Affiliations
- University of Leicester (GB)
- From the National Research Institute, Los Angeles (J.P.F.); the Diabetes Research Centre, University of Leicester, and the National Institute of Health Research Leicester Biomedical Research Centre — both in Leicester, United Kingdom (M.J.D.); the Dallas Diabetes Research Center at Medical City, Dallas (J.R.); Centro de Investigaciones Metabólicas, Buenos Aires (F.C.P.M.); and Eli Lilly, Indianapolis (L.F.L., B.K.B., B.L., X.C., K.B.).
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-08-05
- Volume
- 385
- Issue
- 6
- Pages
- 503-515
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3177122952
- Cited by
- 2,096
- References
- 25
- Citations by year
- 2026: 526 · 2025: 556 · 2024: 396 · 2023: 351 · 2022: 208 · 2021: 57
- FWCI
- 188.92
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- semaglutide, type 2 diabetes, HbA1c, GLP-1 receptor agonists, GIP/GLP-1 dual agonist, non-inferiority, weight loss, gastrointestinal adverse effects, drug safety, dose comparison, glycemic control, adverse drug reactions, hypoglycemia
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Semaglutide, Blood Glucose, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Glucagon-Like Peptides, Female, Gastric Inhibitory Polypeptide, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Metformin, Middle Aged, Nausea, Weight Loss, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.